Mangoceuticals (MGRX) Stock Surges 130% After CEO Lands 500K Share Bonus

TLDR

• MGRX stock jumped over 129% on Monday after an SEC filing revealed CEO Jacob Cohen received 500,000 bonus shares.
• Cohen also moved 200,000 shares to The Tiger Cub Trust, which he controls, bringing the trust’s total to 805,000 shares.
• Trading volume hit over 107 million — compared to a three-month daily average of just 208,000.
• The stock had fallen 54.51% on Friday and is down 78.11% year-to-date.
• The company carries a “Strong Sell” consensus rating with no active price targets from analysts.

Mangoceuticals (MGRX) stock exploded more than 129% on Monday after an SEC filing revealed CEO Jacob Cohen received 500,000 new shares as part of his bonus plan.

Mangoceuticals, Inc., MGRX

Cohen also transferred 200,000 shares to The Tiger Cub Trust, an entity he controls, raising its total stake to 805,000 shares. These two transactions appeared in the same filing, sparking a wave of investor interest.

It’s worth noting the stock had dropped 54.51% just the session before on Friday. MGRX is still down 78.11% year-to-date and 96.59% over the past 12 months.

Monday’s session saw more than 107 million shares change hands. That’s a staggering jump from the stock’s three-month average daily volume of around 208,000.

The stock was trading at around $2.33 per share as of its last recorded close in late October 2025, per MarketBeat data. There are currently no active analyst price targets on file.

Lawsuit and IP Developments

Beyond the share filings, the company has been busy on other fronts. Mangoceuticals disclosed it has filed a civil lawsuit against former technology partner Clarity Ventures, Inc., seeking damages exceeding $73 million. The company alleges failures related to technology services and platform development.

On the intellectual property side, Mangoceuticals filed a PCT international patent application in February for MGX-0024, an antiviral additive technology for use in animal feed and drinking water. The application was filed on February 26, 2026, targeting global patent protection.

Business Operations

The company’s injectable testosterone replacement therapy (TRT) subscription, priced at $99 per month, has been a bright spot. Management cited 336% month-over-month sales growth since mid-December and a 54% drop in customer acquisition costs.

Mangoceuticals also operates MangoRx Direct and PeachesRx Direct, launched in November 2025. These platforms provide access to GLP-1 obesity drugs Zepbound and Wegovy, with pricing starting at around $499 per month on a cash-pay basis.

Despite that operational activity, Wall Street coverage remains thin and cautious. MarketBeat lists one Sell rating and zero Buy or Hold recommendations for the stock.

The consensus analyst stance is “Strong Sell,” and no major brokerages have issued upgrades, downgrades, or new price targets in recent months.

The most recent recorded closing price on file is approximately $2.33 per share from late October 2025.

The post Mangoceuticals (MGRX) Stock Surges 130% After CEO Lands 500K Share Bonus appeared first on CoinCentral.